<DOC>
	<DOCNO>NCT01017042</DOCNO>
	<brief_summary>This study aim characterize pharmacokinetic profile colchicine regimen 1.8 mg two hour . A secondary goal evaluate safety tolerability regimen healthy volunteer . To end , study subject monitor adverse effect throughout entire study period .</brief_summary>
	<brief_title>Pharmacokinetic Study Acute Gout Regimen</brief_title>
	<detailed_description>This study aim characterize pharmacokinetic profile colchicine three main metabolite , regimen 1.8 mg two hour . After fast least 10 hour , fifteen healthy non-smoking , non-obese , non-pregnant adult volunteer age 18 55 give colchicine 1.2 mg ( 2 x 0.6 mg ) orally follow additional single 0.6mg dose one hour later . Fasting continue 4 hour first dose time standardized meal serve . Blood drawn participant time sufficient adequately define pharmacokinetics colchicine 3 major metabolite , 2 , 3 10 demethylcolchicine . A goal study evaluate safety tolerability regimen healthy volunteer . To end , subject monitor throughout participation study adverse reaction study drug and/or procedure . Seated stand blood pressure pulse measure prior first dose 0.5 , 1 , 2 , 4 , 12 hour post-dose . Twelve-lead electrocardiogram obtain time point . All adverse event whether elicited query , spontaneously report , observe clinic staff evaluate Investigator report subject 's case report form .</detailed_description>
	<mesh_term>Colchicine</mesh_term>
	<criteria>Healthy adult 1855 year age , non smoking nonpregnant ( postmenopausal , surgically sterile use effective contraceptive measure ) weigh least 55kg within 15 % ideal body weight . Recent participation ( within 30 day ) research study Recent significant blood donation Pregnant lactate Test positive screening human immunodeficiency virus ( HIV ) , hepatitis B surface antigen ( HbsAg ) , hepatitis C virus ( HCV ) Recent ( 2year ) history evidence alcoholism drug abuse History presence significant cardiovascular , pulmonary , hepatic , renal , haematological , gastrointestinal , endocrine , immunologic , dermatologic , neurological , psychiatric disease Subjects use drug substance know inhibit induce cytochrome ( CYP ) P450 enzymes and/or Pglycoprotein ( Pgp ) within 30 day prior first dose throughout study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>healthy</keyword>
	<keyword>blood level</keyword>
</DOC>